This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Gottlieb, S. O. Articles by Mellits, E. D. Search for Related Content PubMed PubMed Citation Articles by Gottlieb, S. O. Articles by Mellits, E. D.

Circulation, Vol 73, 331-337, Copyright © 1986 by American Heart Association

ARTICLES

Effect of the addition of propranolol to therapy with nifedipine for unstable angina pectoris: a randomized, double-blind, placebo- controlled trial

SO Gottlieb, ML Weisfeldt, P Ouyang, SC Achuff, KL Baughman, TA Traill, JA Brinker, EP Shapiro, NC Chandra and ED Mellits

The value of the addition of beta-blockers to coronary vasodilator therapy in the treatment of patients with unstable angina at rest is controversial. We conducted a double-blind, randomized, placebo- controlled 4 week trial of propranolol in 81 patients with unstable angina, 39 of whom were assigned to placebo and 42 of whom received propranolol in a dose of at least 160 mg daily. All patients were also treated with coronary vasodilators, including 80 mg nifedipine daily and long-acting nitrates. The incidences of cardiac death, myocardial infarction, and requirement for bypass surgery or coronary angioplasty did not differ between the two groups (propranolol = 16; placebo = 18). The propranolol group had a lower cumulative probability of experiencing recurrent resting angina than the placebo group (p = .013), and over the first 4 days of the trial the mean number of clinical episodes of angina (propranolol 0.9 +/- 0.2, placebo 1.8 +/- 0.3, p = .036), duration of angina (propranolol 15.1 +/- 4.3 min, placebo 38.1 +/- 8.4, p = .014), and nitroglycerin requirement (propranolol 1.1 +/- 0.3 tablets, placebo 3.5 +/- 0.8, p = .003) were also fewer. Continuous electrocardiographic recording for ischemic ST segment changes revealed fewer daily ischemic episodes in the propranolol group (2.0 +/- 0.5) than in the placebo group (3.8 +/- 0.7, p = .03), and a shorter duration of ischemia (propranolol 43 +/- 10 min, placebo 104 +/- 28 min, p = .039). Thus propranolol, in patients with unstable angina, in the presence of nitrates and nifedipine is not detrimental and reduces the frequency and duration of symptomatic and silent ischemic episodes.

This article has been cited by other articles:

				A. Kumar and C. P. Cannon Acute Coronary Syndromes: Diagnosis and Management, Part I Mayo Clin. Proc., October 1, 2009; 84(10): 917 - 938. [Abstract] [Full Text] [PDF]

				P.J.L.M. Bernink, M. Rather, J.S. Hochman, and W.J. Rogers Issues in discharge therapy after hospitalization for UA/NSTEMI Eur. Heart J. Suppl., August 1, 2001; 3(suppl_J): J40 - J46. [Abstract] [PDF]

				British Cardiac Society Guidelines and Medical Pra and Royal College of Physicians Clinical Effectiveness Guideline for the management of patients with acute coronary syndromes without persistent ECG ST segment elevation Heart, February 1, 2001; 85(2): 133 - 142. [Full Text]

				M.E Bertrand, M.L Simoons, K.A.A Fox, L.C Wallentin, C.W Hamm, E McFadden, P.J de Feyter, G Specchia, and W Ruzyllo Management of acute coronary syndromes: acute coronary syndromes without persistent ST segment elevation. Recommendations of the Task Force of the European Society of Cardiology: Recommendations of the Task Force of the European Society of Cardiology Eur. Heart J., September 1, 2000; 21(17): 1406 - 1432. [PDF]

				Y. Yeghiazarians, J. B. Braunstein, A. Askari, and P. H. Stone Unstable Angina Pectoris N. Engl. J. Med., January 13, 2000; 342(2): 101 - 114. [Full Text] [PDF]

				N. R. Every, C. P. Cannon, C. Granger, D. J. Moliterno, F. V. Aguirre, J. D. Talley, J. Booth, S. Sapp, J. J. Ferguson, and for the GUARANTEE investigators Influence of insurance type on the use of procedures, medications and hospital outcome in patients with unstable angina: results from the GUARANTEE registry J. Am. Coll. Cardiol., August 1, 1998; 32(2): 387 - 392. [Abstract] [Full Text] [PDF]

				R. P. Giugliano, C. A. Camargo Jr, D. M. Lloyd-Jones, J. D. Zagrodsky, J. D. Alexis, K. A. Eagle, V. Fuster, and C. J. O'Donnell Elderly Patients Receive Less Aggressive Medical and Invasive Management of Unstable Angina: Potential Impact of Practice Guidelines Arch Intern Med, May 25, 1998; 158(10): 1113 - 1120. [Abstract] [Full Text] [PDF]

				P. Theroux and V. Fuster Acute Coronary Syndromes : Unstable Angina and Non–Q-Wave Myocardial Infarction Circulation, March 31, 1998; 97(12): 1195 - 1206. [Full Text] [PDF]

				E. Johnson and T. Ports Unstable Angina Pectoris: An Interventional Approach to Management J Intensive Care Med, July 1, 1988; 3(4): 202 - 214. [Abstract] [PDF]

				Drugs Five Years Later: Nifedipine in Myocardial Ischemia, Systemic Hypertension, and Other Cardiovascular Disorders Ann Intern Med, November 1, 1986; 105(5): 714 - 729. [Abstract] [PDF]